http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2712187-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_befc5ef75cb8433d739d549c2a275688 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1688 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76725725d8aec66d1c43296e56a856a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_776406c63af14a6e3f08b6685f3b5515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6e9b18981ad80e63450bd62072ddf13 |
| publicationDate | 2020-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2712187-C2 |
| titleOfInvention | Pharmaceutical compositions and use thereof |
| abstract | FIELD: medicine; pharmaceuticals. n SUBSTANCE: presented group of inventions refers to pharmaceutical industry, namely to an agent for treating cancer. Pharmaceutical composition for treating cancer, comprising: micronized particles of compound A and/or micronized particles of at least one pharmaceutically acceptable salt of compound A and at least one pharmaceutically acceptable excipient, wherein said micronised particles of compound A and/or micronized particles of at least one pharmaceutically acceptable salt of compound A have particle size distribution (PSD) D90 of less than or equal to 20 mcm, wherein said compound A is N -(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl- 1H -indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulphonamide, presented by formula n (embodiments). n Use of the pharmaceutical composition for preparing a drug for treating cancer. Micronized particles of compound A and/or micronized particles of at least one pharmaceutically acceptable salt of compound A (embodiments). Use of micronized particles of compound A for preparing a drug for treating cancer. Method of treating a subject for which the need to treat cancer is recognized, comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition or micronized particles of compound A. n EFFECT: compositions described above and micronized particles of compound A are characterized by high AUC value in the dosage form, low toxicity, using them reducing cases of vomiting in treating cancer diseases. n 26 cl, 8 dwg, 12 tbl, 4 ex |
| priorityDate | 2015-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 255.